Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended September 30, 2025
Key Event: GSK reported strong Q3 performance, upgrading its full-year 2025 guidance. This is the final quarter reported by CEO Emma Walmsley before transitioning leadership.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | Growth (CER%) |
|---|---|---|---|
| Turnover | £8.5 billion | £8.0 billion | +8% |
| Total Operating Profit | £2.6 billion | £0.2 billion | >100% |
| Total Operating Margin | 30.3% | 2.4% | +28.0 ppts |
| Core Operating Profit | £3.0 billion | £2.8 billion | +11% |
| Core EPS | 55.0p | 49.7p | +14% |
| Cash from Operations | £2.5 billion | £2.5 billion | +1% |
| Free Cash Flow | £1.2 billion | £1.3 billion | -6% |
| Net Debt | £14.4 billion | £12.8 billion | N/A |
Note: Growth percentages are at Constant Exchange Rates (CER) unless otherwise noted. Total results include significant one-off items.
Material Changes vs. Prior Period
- Profit Surge: Total operating profit and EPS increased by over 100% compared to Q3 2024. This is primarily driven by a favorable comparison to a £1.8 billion Zantac legal charge incurred in Q3 2024, lower contingent consideration liability (CCL) charges, and higher other operating income.
- Revenue Growth: Turnover grew 8% at CER, driven by double-digit growth in Specialty Medicines (+16%) and General Medicines (+4%). Vaccines sales were broadly stable (+2%).
- Product Performance:
- Specialty Medicines: HIV sales grew 12% (driven by long-acting injectables Cabenuva and Apretude); Oncology sales surged 39% (driven by Jemperli and Ojjaara/Omjjara); Respiratory, Immunology & Inflammation grew 15% (driven by Nucala and Benlysta).
- Vaccines: Shingrix grew 13% (strong ex-US demand); Arexvy (RSV) grew 36% in Q3 despite a YTD decline due to US inventory dynamics.
- General Medicines: Trelegy grew 25%.
- Balance Sheet: Net debt increased to £14.4 billion due to acquisitions (IDRx, BP Asset IX), dividends, and share buybacks, partially offset by strong free cash flow.
Guidance, Outlook, and Risks
2025 Guidance Upgrade
GSK has upgraded its full-year 2025 guidance at Constant Exchange Rates (CER):
- Turnover Growth: 6% to 7% (previously 3% to 5%).
- Core Operating Profit Growth: 9% to 11% (previously 6% to 8%).
- Core EPS Growth: 10% to 12% (previously 6% to 8%).
Management Commentary
CEO Emma Walmsley highlighted momentum across all business areas, particularly Specialty Medicines. The company achieved four major new product approvals in 2025 (Blenrep, Penmenvy, Blujepa, Nucala for COPD) and has 15 scale pipeline opportunities expected to launch by 2031.
Risks and Contingencies
- Tariffs: Guidance includes tariffs enacted thus far and a potential 15% European tariff impact. The company is monitoring US Section 232 investigations.
- Legal Matters: Zantac litigation continues with trials scheduled for 2026; approximately 14,000 cases dismissed in Federal MDL are on appeal. New patent infringement suits filed regarding Zejula and Breo.
- Vaccine Challenges: Turnover guidance depends on ongoing challenges for Vaccines in the US, specifically Shingrix penetration and Arexvy uptake.
- CEO Transition: Emma Walmsley is concluding her tenure; leadership is transitioning to Luke Gorman.
Investor Verification Checklist
- Core vs. Total Results: Verify the reconciliation between Total and Core results to understand the impact of the £1.8 billion Zantac charge from the prior year and current year impairment charges.
- Vaccine US Performance: Monitor US sales trends for Shingrix and Arexvy, as these are cited as key variables for meeting the upgraded turnover guidance.
- Share Buyback Execution: Confirm progress on the £2 billion share buyback programme (currently £1.1 billion spent YTD) and its impact on EPS.
- Legal Provisions: Review the aggregate provision for legal disputes (£731 million) and updates on Zantac litigation outcomes.
- Pipeline Milestones: Track upcoming regulatory decisions for depemokimab (asthma/nasal polyps) expected in December 2025 and gepotidacin (gonorrhoea) in December 2025.